FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jørn Herrstedt

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Troels K Bergmann; Lise Eckhoff; Søren Feddersen; Henrik Gréen; Jørn Herrstedt; Werner Vach; Kim Brosen
GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.
Rikke H Dahlrot; Jørn Herrstedt; Jacob Hjelmborg; Bjarne W Kristensen; S Hansen
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Trine Lembrecht Jørgensen; Merete Paludan; Laurids Østergaard Poulsen; Sandra Teiblum; Karin Herskind Bruun; Jesper Hallas; Anni Young Stensgård Jørgensen; Jørn Herrstedt
Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jørn Herrstedt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Troels K Bergmann; Lise Eckhoff; Søren Feddersen; Henrik Gréen; Jørn Herrstedt; Werner Vach; Kim Brosen
GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.
Acta oncologica (Stockholm, Sweden) 2013;52(4):871-4.
2013: Rikke H Dahlrot; Jørn Herrstedt; Jacob Hjelmborg; Bjarne W Kristensen; S Hansen
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
International journal of clinical and experimental pathology 2013;6(1):31-40.
2012: Trine Lembrecht Jørgensen; Merete Paludan; Laurids Østergaard Poulsen; Sandra Teiblum; Karin Herskind Bruun; Jesper Hallas; Anni Young Stensgård Jørgensen; Jørn Herrstedt
Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.
Gynecologic oncology 2012;127(2):367-74.
2012: Christina H Ruhlmann; Jørn Herrstedt
Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Expert review of anticancer therapy 2012;12(2):139-50.
2011: Troels K Bergmann; Charlotte Brasch-Andersen; Kim Brosen; Per Damkier; Andreas du Bois; Henrik Gréen; Jørn Herrstedt; Berit Hølund; Mansoor R Mirza; Werner Vach; Curt Peterson
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
European journal of clinical pharmacology 2011;67(7):693-700.
2011: Jørn Herrstedt; Declan Walsh
Introduction: Supportive care and palliative medicine.
Seminars in oncology 2011;38(3):335-6.
2011: Julie Midtgaard; Maria Stage; Tom Møller; Christina Andersen; Morten Quist; Mikael Rørth; Jørn Herrstedt; Kirsten Vistisen; Birgitte Christiansen; Lis Adamsen
Exercise may reduce depression but not anxiety in self-referred cancer patients undergoing chemotherapy. Post-hoc analysis of data from the 'Body & Cancer' trial.
Acta oncologica (Stockholm, Sweden) 2011;50(5):660-9.
2011: Christina H Ruhlmann; Jørn Herrstedt
Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Expert opinion on drug safety 2011;10(3):449-62.
2011: Steven M Grunberg; Daniel Chua; Anish Maru; José Dinis; Suzanne DeVandry; Judith A Boice; James S Hardwick; Elizabeth Beckford; Arlene Taylor; Alexandra Carides; Fausto Roila; Jørn Herrstedt
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(11):1495-501.
2011: Ian Olver; Alexander Molassiotis; Matti Aapro; Jørn Herrstedt; Steven Grunberg; Garry Morrow
Antiemetic research: future directions.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19 Suppl 1():S49-55.
2011: Mark G Kris; Maurizio Tonato; Emilio Bria; Enzo Ballatori; Birgitte Espersen; Jørn Herrstedt; Cynthia N Rittenberg; Lawrence H Einhorn; Steven M Grunberg; Mitsue Saito; Gary Morrow; Paul J Hesketh
Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19 Suppl 1():S25-32.
2011: Jørn Herrstedt; Bernardo Rapoport; David Warr; Fausto Roila; Emilio Bria; Cynthia Rittenberg; Paul J Hesketh
Acute emesis: moderately emetogenic chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19 Suppl 1():S15-23.
2010: Andreas du Bois; Jørn Herrstedt; Anne-Claire Hardy-Bessard; Hans-Helge Müller; Philipp Harter; Gunnar Kristensen; Florence Joly; Jens Huober; Elisabeth Avall-Lundqvist; Béatrice Weber; Christian Kurzeder; Svetislav Jelic; Eric Pujade-Lauraine; Alexander Burges; Jacobus Pfisterer; Martina Gropp; Anne Staehle; Pauline Wimberger; Christian Jackisch; Jalid Sehouli
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(27):4162-9.
2010: Christina Ruhlmann; Jørn Herrstedt
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Expert review of anticancer therapy 2010;10(2):137-48.
2009: Jørn Herrstedt; Wichit Apornwirat; Ahmed Shaharyar; Zeba Aziz; Fausto Roila; Simon Van Belle; Mark W Russo; Jeremey Levin; Salabha Ranganathan; Mary Guckert; Steven M Grunberg
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5363-9.
2009: Jørn Herrstedt
Antiemetics: state of the art.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():439-41.
2009: Jan Nyrop Jakobsen; Jørn Herrstedt
Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients.
Critical reviews in oncology/hematology 2009;71(3):214-21.
2009: Jørn Herrstedt
Controlling chemotherapy-related nausea and vomiting.
The lancet oncology 2009;10(6):636.
2009: Steven M Grunberg; Janusz Rolski; Janos Strausz; Zeba Aziz; Stephen Lane; Mark W Russo; Paul Wissel; Mary Guckert; Oliver Wright; Jørn Herrstedt
Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
The lancet oncology 2009;10(6):549-58.
2009: Jørn Herrstedt; F Roila
Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():156-8.
2009: Christina Ruhlmann; Jørn Herrstedt
Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.
Therapeutics and clinical risk management 2009;5(2):375-84.
2009: Jørn Herrstedt
The difficult trials.
Onkologie 2009;32(1-2):7-8.
2009: Lis Adamsen; Morten Quist; Christina Andersen; Tom Møller; Jørn Herrstedt; Dorte Kronborg; Marie T Baadsgaard; Kirsten Vistisen; Julie Midtgaard; Birgitte Christiansen; Maria Stage; Morten T Kronborg; Mikael Rørth
Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial.
BMJ (Clinical research ed.) 2009;339():b3410.
2008: Jørn Herrstedt; F Roila
Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 2():ii110-2.
2008: Eva Ellebaek; Jørn Herrstedt
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Current opinion in supportive and palliative care 2008;2(1):28-34.
2008: Jørn Herrstedt
Antiemetics: an update and the MASCC guidelines applied in clinical practice.
Nature clinical practice. Oncology 2008;5(1):32-43.
2007: Jørn Herrstedt; Per Dombernowsky
Anti-emetic therapy in cancer chemotherapy: current status.
Basic & clinical pharmacology & toxicology 2007;101(3):143-50.
2007: Jørn Herrstedt; TC Sigsgaard; H A Nielsen; J Handberg; Seppo Langer; S Ottesen; Per Dombernowsky
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(4):417-26.
2007: Jørn Herrstedt
[Medical treatment of chemotherapy-induced nausea and vomiting].
Ugeskrift for laeger 2007;169(9):799-805.
2006: Brigitte Bloechl-Daum; Robert Deuson; Panagiotis Mavros; Mogens Hansen; Jørn Herrstedt
Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(27):4472-8.
2006: Paul J Hesketh; Steven M Grunberg; Jørn Herrstedt; Ronald de Wit; Richard J Gralla; Alexandra D Carides; Arlene Taylor; Judith K Evans; kevin horgan
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2006;14(4):354-60.
2006: Kamma Bertelsen; Anders Jakobsen; Jørn Herrstedt; Lone Kjeld Petersen; Berit Hølund; Estrid Staehr Hansen; Erik Soegaard Andersen; Jens B Knudsen; Lotte Nedergaard Thomsen
[Treatment of cervix cancer with radical hysterectomy is a task for district departments].
Ugeskrift for laeger 2006;168(6):600; author reply 600-1.
2006: Fausto Roila; Paul J Hesketh; Jørn Herrstedt
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):20-8.
2005: Jørn Herrstedt; Hyman Muss; David Warr; Paul J Hesketh; Peter D Eisenberg; Harry Raftopoulos; Steven M Grunberg; Munir Gabriel; Anthony Rodgers; Carolyn M Hustad; kevin horgan; Franck Skobieranda
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
Cancer 2005;104(7):1548-55.
2005: Richard J Gralla; Ronald de Wit; Jørn Herrstedt; Alexandra D Carides; Juliana Ianus; Julie Guoguang-Ma; Judith K Evans; kevin horgan
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Cancer 2005;104(4):864-8.
2005: David Warr; Paul J Hesketh; Richard J Gralla; Hyman Muss; Jørn Herrstedt; Peter D Eisenberg; Harry Raftopoulos; Steven M Grunberg; Munir Gabriel; Anthony Rodgers; Norman Bohidar; George Klinger; Carolyn M Hustad; kevin horgan; Franck Skobieranda
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2822-30.
2005: Mark G Kris; Paul J Hesketh; Jørn Herrstedt; Cynthia N Rittenberg; Lawrence H Einhorn; Steven M Grunberg; Jim M Koeller; Ian Olver; Sussanne Borjeson; Enzo Ballatori
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):85-96.
2005: Jørn Herrstedt; Jim M Koeller; Fausto Roila; Paul J Hesketh; David Warr; Cynthia N Rittenberg; Mario Dicato
Acute emesis: moderately emetogenic chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):97-103.
2005: Fausto Roila; David Warr; Rebecca A Clark-Snow; Maurizio Tonato; Richard J Gralla; Lawrence H Einhorn; Jørn Herrstedt
Delayed emesis: moderately emetogenic chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):104-8.
2005: Jørn Herrstedt; M S Aapro; Fausto Roila; V V Kataja
ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 1():i77-9.
2004: Jørn Herrstedt
Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Expert opinion on drug safety 2004;3(3):231-48.
2004: Ronald de Wit; Jørn Herrstedt; B Rapoport; Alexandra D Carides; J Guoguang-Ma; Mary E Elmer; Carrie Schmidt; Judith K Evans; kevin horgan
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
European journal of cancer (Oxford, England : 1990) 2004;40(3):403-10.
2003: Ronald de Wit; Jørn Herrstedt; B Rapoport; Alexandra D Carides; G Carides; Mary E Elmer; Carrie Schmidt; Judith K Evans; kevin horgan
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4105-11.
2002: Jørn Herrstedt
Nausea and emesis: still an unsolved problem in cancer patients?
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2002;10(2):85-7.
2002: Lise Pedersen; Anders Bonde Jensen; Bent Enig; Peter Vejby Hansen; Jørn Herrstedt; Niels Viggo Jensen; Nina Keldsen; Torben Palshof
[Palliative medicine education].
Ugeskrift for laeger 2002;164(4):500-2.
2001: TC Sigsgaard; Jørn Herrstedt; J Handberg; M Kjaer; Per Dombernowsky
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2091-7.
2000: Jørn Herrstedt
Prevention and management of mucositis in patients with cancer.
International journal of antimicrobial agents 2000;16(2):161-3.
2000: M Sorensen; Peter B Jensen; Jørn Herrstedt; Fred R Hirsch; Heine H Hansen
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):829-35.
2000: TC Sigsgaard; Jørn Herrstedt; P Christensen; O Andersen; Per Dombernowsky
Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000;8(3):233-7.
1999: TC Sigsgaard; Jørn Herrstedt; Lars Juel Andersen; H Havsteen; Seppo Langer; A G Kjaerbøl; H Lund; M Kjaer; Per Dombernowsky
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
British journal of cancer 1999;80(3-4):412-8.
1998: Jørn Herrstedt; M S Aapro; J F Smyth; Albano Del Favero
Corticosteroids, dopamine antagonists and other drugs.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(3):204-14.
1998: J Handberg; V Wessel; L Larsen; Jørn Herrstedt; Heine H Hansen
Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(1):63-7.
1998: Jørn Herrstedt
Antiemetic research: a look to the future.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(1):8-12.
1997: Enzo Ballatori; Fausto Roila; Verena de Angelis; G Ciccarese; MA Palladino; Maurizio Tonato; Albano Del Favero; Jørn Herrstedt; Mario Dicato; Andreas du Bois; Paul J Hesketh; Mark G Kris; Richard J Gralla
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(4):269-73.
1997: Jørn Herrstedt; TC Sigsgaard; J Handberg; B M Schousboe; M Hansen; Per Dombernowsky
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1690-6.
1997: Jørn Herrstedt; TC Sigsgaard; Helle Riis Angelo; Jens Peter Kampmann; M Hansen
Dose-finding study of oral metopimazine.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(1):38-43.
1996: Jørn Herrstedt; M Jørgensen; H R Angelo; M R Rassing; J Møller-Sonnergaard; Per Dombernowsky
Bioavailability of the antiemetic metopimazine given as a microenema.
British journal of clinical pharmacology 1996;41(6):613-5.
1995: Jørn Herrstedt
Development of antiemetic therapy in cancer patients.
Acta oncologica (Stockholm, Sweden) 1995;34(5):637-40.
1994: Jørn Herrstedt
We still need common criteria for the assessment of nausea and vomiting.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1217.
1993: Jørn Herrstedt; T Sigsgaard; M Boesgaard; T P Jensen; Per Dombernowsky
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
The New England journal of medicine 1993;328(15):1076-80.
1993: L E Stenbygaard; Jørn Herrstedt; J F Thomsen; K R Svendsen; Svend A Engelholm; Per Dombernowsky
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.
Breast cancer research and treatment 1993;25(1):57-63.
1993: Jørn Herrstedt; J Hyttel; J Pedersen
Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.
Cancer chemotherapy and pharmacology 1993;33(1):53-6.
1992: Jørn Herrstedt; P Clementsen; O P Hansen
Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1992;28A(6-7):1070-3.
1991: Jørn Herrstedt; Jens Hannibal; J Hallas; E Andersen; L C Laursen; M Hansen
High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(3):223-7.
1990: Jørn Herrstedt; M Jørgensen; H R Angelo
The effect of food on serum concentrations of metopimazine.
British journal of clinical pharmacology 1990;30(2):237-43.
1990: V B Løgager; A Vestergaard; Jørn Herrstedt; Henrik S Thomsen; K Zedeler; Per Dombernowsky
The limited value of routine chest X-ray in the follow-up of stage II breast cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(5):553-5.
1989: H R Angelo; Jørn Herrstedt; M Jørgensen
High-performance liquid chromatographic method with fluorescence detection for the simultaneous determination of metopimazine and its acid metabolite in serum.
Journal of chromatography 1989;496(2):472-7.
1989: A Vestergaard; Jørn Herrstedt; Henrik S Thomsen; Per Dombernowsky; K Zedeler
The value of yearly chest X-ray in patients with stage I breast cancer.
European journal of cancer & clinical oncology 1989;25(4):687-9.